Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201

Entrada Therapeutics (TRDA) announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy who are amenable to exon 45 skipping. “ELEVATE-45-201 is the most advanced clinical study of a conjugated exon skipping therapy for individuals amenable to exon 45 skipping and offers the potential to address a large Duchenne subpopulation with significant unmet medical needs,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “The EU authorization builds on the growing clinical momentum behind our novel Duchenne programs. With the recent authorizations of ELEVATE-44 and ELEVATE-45, and a planned filing for ELEVATE-50 later this year, we are on track to significantly expand the scope of our DMD franchise by year-end.”